Email Alert RSS
Volume 12 Issue 4
Jul.  2021
Turn off MathJax
Article Contents
Article Navigation >  Medical Journal of Peking Union Medical College Hospital  > 2021  >  12(4): 537-543
LIANG Xiaojie, WANG Liang. Current Status of the Diagnosis and Treatment of Primary Intraocular Lymphoma[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(4): 537-543. doi: 10.12290/xhyxzz.20190100
Citation: LIANG Xiaojie, WANG Liang. Current Status of the Diagnosis and Treatment of Primary Intraocular Lymphoma[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(4): 537-543. doi: 10.12290/xhyxzz.20190100
shu

Current Status of the Diagnosis and Treatment of Primary Intraocular Lymphoma

doi: 10.12290/xhyxzz.20190100
  • 1.

    First Clinical Medical College, Southern Medical University, Guangzhou 510515, China

  • 2.

    Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China

Funds:

National Natural Science Foundation of China 81873450

More Information
  • Corresponding author: WANG Liang  Tel：86-10-58268442，E-mail：wangliangtrhos@126.com
  • Received Date: 2019-06-04
  • Accepted Date: 2019-10-12
    • Available Online: 2019-10-12
  • Publish Date: 2021-07-30
    Abstract
  • Primary intraocular lymphoma (PIOL) is a rare non-Hodgkin lymphoma and classified as a special subtype of primary central nervous system lymphoma (PCNSL). At present, the diagnosis of PIOL still faces some challenges because it can masquerade as uveitis, behcet disease and so on. Its histopathologic biopsy remains the standard approach to diagnose PIOL. Gene detection, flow cytometry analysis, and determination of cytokine levels can increase the diagnostic accuracy of PIOL. Currently, there are no standard therapies for PIOL, although local radiotherapy, intravitreal chemotherapy and high-dose systemic chemotherapy are effective to control it. However, the prognosis of PIOL is poor because it is prone to local recurrence and developing into PCNSL.Therefore, early diagnosis and treatment are very important for the prognosis of PIOL.
    • FullText(HTML)
  • loading
    • References(45)
  • [1] Tang LJ, Gu CL, Zhang P. Intraocular lymphoma[J]. Int J Ophthalmol, 2017, 10: 1301-1307.
    [2] Chaput F, Amer R, Baglivo E, et al. Intraocular T-cell Lymphoma: Clinical Presentation, Diagnosis, Treatment, and Outcome[J]. Ocul Immunol Inflamm, 2017, 25: 639-648. http://europepmc.org/abstract/MED/27002464
    [3] Bohn JP, Willenbacher W, Haas G, et al. Pomalidomide in primary intraocular lymphoma[J]. Leuk Lymphoma, 2019, 60: 1584-1586. doi:  10.1080/10428194.2018.1538508
    [4] Cho BJ, Yu HG. Risk factors for intraocular involvement in patients with primary central nervous system lymphoma[J]. J Neurooncol, 2014, 120: 523-529. doi:  10.1007/s11060-014-1581-4
    [5] Mochizuki M, Singh AD. Epidemiology and clinical features of intraocular lymphoma[J]. Ocul Immunol Inflamm, 2009, 17: 69-72. doi:  10.1080/09273940902957305
    [6] Goto H, Mochizuki M, Yamaki K, et al. Epidemiological survey of intraocular inflammation in Japan[J]. Jpn J Ophthalmol, 2007, 51: 41-44. doi:  10.1007/s10384-006-0383-4
    [7] Sagoo MS, Mehta H, Swampillai AJ, et al. Primary intraocular lymphoma[J]. Surv Ophthalmol, 2014, 59: 503-516. doi:  10.1016/j.survophthal.2013.12.001
    [8] Chan CC, Rubenstein JL, Coupland SE, et al. Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium[J]. Oncologist, 2011, 16: 1589-1599. doi:  10.1634/theoncologist.2011-0210
    [9] Chan CC. Primary intraocular lymphoma: clinical features, diagnosis, and treatment[J]. Clin Lymphoma, 2003, 4: 30-31. doi:  10.1016/S1526-9655(11)70005-7
    [10] Kimura K, Usui Y, Goto H. Clinical features and diagno-stic significance of the intraocular fluid of 217 patients with intraocular lymphoma[J]. Jpn J Ophthalmol, 2012, 56: 383-389. doi:  10.1007/s10384-012-0150-7
    [11] Mashayekhi A, Shukla SY, Shields JA, et al. Choroidal lymphoma: clinical features and association with systemic lymphoma[J]. Ophthalmology, 2014, 121: 342-351. doi:  10.1016/j.ophtha.2013.06.046
    [12] Kiratli H, Ağin A, Büyükeren B, et al. Primary Diffuse Large B-Cell Lymphoma of the Ciliary Body[J]. Ocul Immunol Inflamm, 2019, 27: 407-409. doi:  10.1080/09273948.2017.1415362
    [13] Chan CC, Sen HN. Current concepts in diagnosing and managing primary vitreoretinal (intraocular) lymphoma[J]. Discov Med, 2013, 15: 93-100.
    [14] Casady M, Faia L, Nazemzadeh M, et al. Fundus autofluorescence patterns in primary intraocular lymphoma[J]. Retina, 2014, 34: 366-372. doi:  10.1097/IAE.0b013e31829977fa
    [15] Majumder PD, Raghothaman N, Kharel R, et al. Retinal necrosis as the initial presentation of primary intraocular lymphoma[J]. Nepal J Ophthalmol, 2017, 9: 83-86. doi:  10.3126/nepjoph.v9i1.17541
    [16] Grimm SA, McCannel CA, Omuro AM, et al. Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report[J]. Neurology, 2008, 71: 1355-1360. doi:  10.1212/01.wnl.0000327672.04729.8c
    [17] Hwang CS, Yeh S, Bergstrom CS. Diagnostic vitrectomy for primary intraocular lymphoma: when, why, how?[J]. Int Ophthalmol Clin, 2014, 54: 155-171. doi:  10.1097/IIO.0000000000000022
    [18] Fend F, Ferreri AJ, Coupland SE. How we diagnose and treat vitreoretinal lymphoma[J]. Br J Haematol, 2016, 173: 680-692. doi:  10.1111/bjh.14025
    [19] Konstantinidis L, Angi M, Coupland SE, et al. Primary B-cell lymphoma of the ciliary body with 360° ('ring'-like) growth pattern[J]. Eye (Lond), 2014, 28: 355-356. doi:  10.1038/eye.2013.282
    [20] Hoang-Xuan K, Bessell E, Bromberg J, et al. Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology[J]. Lancet Oncol, 2015, 16: e322-e332. doi:  10.1016/S1470-2045(15)00076-5
    [21] Keino H, Okada AA, Watanabe T, et al. Spectral-domain Optical Coherence Tomography Patterns in Intraocular Lymphoma[J]. Ocul Immunol Inflamm, 2016, 24: 268-273. http://europepmc.org/abstract/med/25760916
    [22] Fardeau C, Lee CP, Merle-Béral H, et al. Retinal fluorescein, indocyanine green angiography, and optic coher-ence tomography in non-Hodgkin primary intraocular lymphoma[J]. Am J Ophthalmol, 2009, 147: 886-894. doi:  10.1016/j.ajo.2008.12.025
    [23] Davis JL, Viciana AL, Ruiz P. Diagnosis of intraocular lymphoma by flow cytometry[J]. Am J Ophthalmol, 1997, 124: 362-372. doi:  10.1016/S0002-9394(14)70828-1
    [24] Missotten T, Tielemans D, Bromberg JE, et al. Multicolor flowcytometric immunophenotyping is a valuable tool for detection of intraocular lymphoma[J]. Ophthalmology, 2013, 120: 991-996. doi:  10.1016/j.ophtha.2012.11.007
    [25] Hiemcke-Jiwa LS, Ten Dam-van Loon NH, Leguit RJ, et al. Potential Diagnosis of Vitreoretinal Lymphoma by Detection of MYD88 Mutation in Aqueous Humor With Ultrasensitive Droplet Digital Polymerase Chain Reaction[J]. JAMA Ophthalmol, 2018, 136: 1098-1104. doi:  10.1001/jamaophthalmol.2018.2887
    [26] Tuo J, Shen D, Yang HH, et al. Distinct microRNA-155 expression in the vitreous of patients with primary vitreore-tinal lymphoma and uveitis[J]. Am J Ophthalmol, 2014, 157: 728-734. doi:  10.1016/j.ajo.2013.12.014
    [27] Ohta K, Sano K, Imai H, et al. Cytokine and molecular analyses of intraocular lymphoma[J]. Ocul Immunol Inflamm, 2009, 17: 142-147. doi:  10.1080/09273940802702553
    [28] Cassoux N, Giron A, Bodaghi B, et al. IL-10 measurement in aqueous humor for screening patients with suspicion of primary intraocular lymphoma[J]. Invest Ophthalmol Vis Sci, 2007, 48: 3253-3259. doi:  10.1167/iovs.06-0031
    [29] Wolf LA, Reed GF, Buggage RR, et al. Vitreous cytokine levels[J]. Ophthalmology, 2003, 110: 1671-1672. doi:  10.1016/S0161-6420(03)00811-X
    [30] Kim MM, Dabaja BS, Medeiros J, et al. Survival Outcomes of Primary Intraocular Lymphoma: A Single-institution Experience[J]. Am J Clin Oncol, 2016, 39: 109-113. doi:  10.1097/COC.0000000000000028
    [31] Levasseur SD, Wittenberg LA, White VA. Vitreoretinal lymphoma: a 20-year review of incidence, clinical and cytologic features, treatment, and outcomes[J]. JAMA Ophthalmol, 2013, 131: 50-55. doi:  10.1001/jamaophthalmol.2013.569
    [32] Milgrom SA, Cheah CY, Pinnix CC, et al. Acute and late toxicity of bilateral orbital irradiation in the management of primary intraocular lymphoma[J]. Leuk Lymphoma, 2016, 57: 2612-2618. doi:  10.3109/10428194.2016.1166490
    [33] Teckie S, Yahalom J. Primary intraocular lymphoma: treatment outcomes with ocular radiation therapy alone[J]. Leuk Lymphoma, 2014, 55: 795-801. doi:  10.3109/10428194.2013.819576
    [34] Ma WL, Hou HA, Hsu YJ, et al. Clinical outcomes of primary intraocular lymphoma patients treated with front-line systemic high-dose methotrexate and intravitreal methotrexate injection[J]. Ann Hematol, 2016, 95: 593-601. doi:  10.1007/s00277-015-2582-x
    [35] Tempescul A, Pradier O, Marianowski-Cochard C, et al. Combined therapy associating systemic platinum-based chemotherapy and local radiotherapy into the treatment of primary intraocular lymphoma[J]. Ann Hematol, 2011, 90: 1117-1118. doi:  10.1007/s00277-010-1139-2
    [36] Frenkel S, Hendler K, Siegal T, et al. Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience[J]. Br J Ophthalmol, 2008, 92: 383-388. doi:  10.1136/bjo.2007.127928
    [37] Kitzmann AS, Pulido JS, Mohney BG, et al. Intraocular use of rituximab[J]. Eye (Lond), 2007, 21: 1524-1527. doi:  10.1038/sj.eye.6702804
    [38] Kim H, Csaky KG, Chan CC, et al. The pharmacok-inetics of rituximab following an intravitreal injection[J]. Exp Eye Res, 2006, 82: 760-766. doi:  10.1016/j.exer.2005.09.018
    [39] Ghesquieres H, Chevrier M, Laadhari M, et al. Lenalido-mide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective'proof of concept'phase Ⅱ study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†[J]. Ann Oncol, 2019, 30: 621-628. doi:  10.1093/annonc/mdz032
    [40] Lionakis MS, Dunleavy K, Roschewski M, et al. Inhibi-tion of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma[J]. Cancer Cell, 2017, 31: 833-843. doi:  10.1016/j.ccell.2017.04.012
    [41] Wang L, Guan W, Peng X. Targeting Bruton Tyrosine Kinase With Zanubrutinib for Treatment of Vitreoretinal Lymphoma: Report of 3 Cases[J]. Front Oncol, 2021, 11: 676792. doi:  10.3389/fonc.2021.676792
    [42] Goodman A, Patel SP, Kurzrock R. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas[J]. Nat Rev Clin Oncol, 2017, 14: 203-220. doi:  10.1038/nrclinonc.2016.168
    [43] Nayak L, Iwamoto FM, LaCasce A, et al. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma[J]. Blood, 2017, 129: 3071-3073. doi:  10.1182/blood-2017-01-764209
    [44] Schorb E, Finke J, Ihorst G, et al. Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients[J]. BMC Cancer, 2019, 19: 287. doi:  10.1186/s12885-019-5473-z
    [45] Ferreri AJ, Blay JY, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience[J]. J Clin Oncol, 2003, 21: 266-272. doi:  10.1200/JCO.2003.09.139
    • Relative Articles(0)
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1005) PDF downloads(199) Cited by()
    Proportional views
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return